Clozapine plasma level monitoring: Current status

被引:37
作者
Cooper, TB
机构
[1] COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10027
[2] NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032
关键词
D O I
10.1007/BF02326373
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Plasma level monitoring of clozapine and metabolites may prove beneficial in treating patients who show unusual drug metabolic activity. A threshold plasma level for patients who will respond to this medication is suggested. The interaction of gender, age, smoking, other medication and side effects with plasma clozapine and metabolites are discussed. Plasma level monitoring of clozapine and/or metabolites is recommended in patients who do not respond at usual therapeutic dose, who show untoward side effects at low dose or who are treated with other medications. Finally monitoring of patients who require more than 600 mg/day should be implemented because there is evidence that the incidence of seizures increases significantly above this dosage level. There is some evidence that high plasma clozapine levels are associated with seizures.
引用
收藏
页码:297 / 311
页数:15
相关论文
共 73 条
[1]  
ACKENHEIL M, 1976, ARZNEIMITTEL-FORSCH, V26, P1156
[2]   CYTOCHROME P4502D6 GENOTYPE DOES NOT DETERMINE RESPONSE TO CLOZAPINE [J].
ARRANZ, MJ ;
DAWSON, E ;
SHAIKH, S ;
SHAM, P ;
SHARMA, T ;
AITCHISON, K ;
CROCQ, MA ;
GILL, M ;
KERWIN, R ;
COLLIER, DA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (04) :417-420
[3]   CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST [J].
BERTILSSON, L ;
CARRILLO, JA ;
DAHL, ML ;
LLERENA, A ;
ALM, C ;
BONDESSON, U ;
LINDSTROM, L ;
DELARUBIA, IR ;
RAMOS, S ;
BENITEZ, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :471-473
[4]  
BONDESSON U, 1988, PSYCHOPHARMACOLOGY, V95, P472
[5]  
BRAU VH, 1978, ARZNEIMITTEL-FORSCH, P1300
[6]   FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2 [J].
BROSEN, K ;
SKJELBO, E ;
RASMUSSEN, BB ;
POULSEN, HE ;
LOFT, S .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1211-1214
[7]  
CENTORRINO F, 1995, AM J PSYCHIAT, V152, P610
[8]  
CENTORRINO F, 1994, AM J PSYCHIAT, V151, P123
[9]  
CHIEN CP, ETHNIC VARIATION PLA
[10]   SINGLE-DOSE VS MULTIPLE-DOSE PHARMACOKINETICS OF CLOZAPINE IN PSYCHIATRIC-PATIENTS [J].
CHOC, MG ;
HSUAN, F ;
HONIGFELD, G ;
ROBINSON, WT ;
ERESHEFSKY, L ;
CRISMON, ML ;
SAKLAD, SR ;
HIRSCHOWITZ, J ;
WAGNER, R .
PHARMACEUTICAL RESEARCH, 1990, 7 (04) :347-351